PriceTargets.com logo

Novacyt - NCYT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 65.07 As of 04/23/2024 08:04 AM ET
▼ -1.935 (-2.89%)

This chart shows the closing price for NCYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novacyt Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NCYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NCYT

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Novacyt in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 65.07.

This chart shows the closing price for NCYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Novacyt. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/18/2021Numis SecuritiesReiterated RatingBuyGBX 570
6/29/2021Numis SecuritiesReiterated RatingBuyGBX 570
5/17/2021Numis SecuritiesReiterated RatingBuyGBX 570
3/11/2021Oddo BhfInitiated CoverageNeutral
3/11/2021Oddo SecuritiesInitiated CoverageNeutral
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Novacyt logo
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Read More

Today's Range

Now: GBX 65.07
Low: 64.15
High: 67.38

50 Day Range

MA: GBX 48.03
Low: 43
High: 70

52 Week Range

Now: GBX 65.07
Low: 35.80
High: 86

Volume

53,978 shs

Average Volume

71,132 shs

Market Capitalization

£45.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Novacyt?

The following Wall Street analysts have issued stock ratings on Novacyt in the last twelve months:
View the latest analyst ratings for NCYT.

What is the current price target for Novacyt?

0 Wall Street analysts have set twelve-month price targets for Novacyt in the last year. has the lowest price target set, forecasting a price of £100,000 for Novacyt in the next year.
View the latest price targets for NCYT.

What is the current consensus analyst rating for Novacyt?

Novacyt currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NCYT.

What other companies compete with Novacyt?

Other companies that are similar to Novacyt include Intelligent Ultrasound Group, Inspiration Healthcare Group, Belluscura, Creo Medical Group and EKF Diagnostics. Learn More about companies similar to Novacyt.

How do I contact Novacyt's investor relations team?

Novacyt's physical mailing address is 13 Avenue Morane Saulnier, Vélizy-Villacoublay 78140, France. The company's listed phone number is 33 1 39 46 51 04. The official website for Novacyt is www.novacyt.com. Learn More about contacing Novacyt investor relations.